Twenty-four hours ago Brent crude was above $97 and the ceasefire was dead. This morning it is back around $93 after diplomatic channels between Washington and Tehran reportedly reopened overnight.
WTI is trading around $89, down roughly $6 from yesterday's spike. Both sides are reportedly signaling willingness to return to the ceasefire framework that held through April and May, with the Strait of Hormuz remaining the central piece of any deal. If a deal materializes this week, Brent likely tests the mid-$80s. If talks stall again, $100 returns fast.
For the energy sector, the question is not where crude settles today but how long the disruption premium lasts. Refiners like Valero and upstream producers like Occidental hold up better than most in either scenario because their cash flows are levered to sustained elevation, not to a single-day spike. We covered yesterday's surge here.
The timing of this oil reversal matters because of what lands tomorrow.
May CPI drops at 8:30 AM Wednesday. Consensus expects headline at 4.2% year over year, up from April's 3.8%, with energy costs again driving the acceleration. That would be the highest headline print since April 2023.
Core CPI is forecast at 2.9%. The gap between headline and core is the number to watch. If headline runs hot while core stays anchored, inflation is still primarily a fuel story, and the Fed may read it differently than a broad-based acceleration.
But a hot headline still matters for the dot plot. Another month of acceleration makes it increasingly difficult for any official to project cuts this year at the June 16-17 meeting. The market has already priced out cuts for 2026. What CPI determines now is whether expectations tip from "no cuts" toward "the next move is up."
GSK is acquiring Nuvalent for $10.6 billion. NUVL surged roughly 39% in premarket to around $124, a 40% premium to Monday's close. The deal delivers three late-stage lung cancer drugs, including two next-generation inhibitors targeting ROS1 and ALK mutations in non-small cell lung cancer.
It is GSK's largest deal in more than a decade. GSK held its full-year guidance unchanged at 7% to 9% core profit growth and expects the deal to contribute revenue starting in 2027. The premium signals that big pharma will pay full price for clinical-stage oncology assets even with borrowing costs elevated. For biotech investors, deal flow at these valuations means the sector's appetite for late-stage pipelines has not dried up despite higher rates compressing small-cap multiples elsewhere.
The chip rebound is extending. Micron is up roughly 5% in premarket after falling 13% Friday. Futures are building on Monday's session, which saw the S&P 500 close up 0.30% at 7,405.73 and the Nasdaq rise 0.86% to 25,929.66. The Dow dipped 0.16% to 50,786. Whether the semiconductor bounce holds through the week depends entirely on tomorrow's CPI. A hot print sends rate-sensitive growth names right back into the sell queue.
SpaceX prices after the close Thursday. At $135 per share and a $1.77 trillion valuation, the offering targets $75 billion in proceeds, the largest IPO in U.S. history. At that figure, SpaceX would rank as the seventh-largest company in the U.S. by market cap. First trades are expected Friday on the Nasdaq under SPCX. Every late-stage private company eyeing a 2026 listing is watching whether institutional demand holds at this price.
Gold is holding around $4,350 this morning despite the geopolitical uncertainty, weighed down by yields near 4.50% that make Treasuries more competitive against non-yielding assets.
CPI tomorrow morning. SpaceX Thursday evening. FOMC one week from today. The next 72 hours carry more directional risk than any stretch since early April.
